Literature DB >> 18703276

Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression.

Li Hua Zheng1, Yong Li Bao, Yin Wu, Chun Lei Yu, Xiangying Meng, Yu Xin Li.   

Abstract

Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment. In this study, we established an in vitro multiple drug resistant HepG2 cell line (HepG2/ADM), and characterized its MDR. This model was used to screen potential candidate chemosensitisers from over 200 purified naturally occurring compounds extracted from plants and animals. Cantharidin was found to have a significant reversal on MDR in our model. Further, our results showed that Cantharidin could significantly inhibit P-gp (P-glycoprotein) expression, mRNA transcription, as well as MDR1 promoter activity. These results suggest that Cantharidin is a novel and potent MDR reversal agent and may be a potential adjunctive agent for tumor chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18703276     DOI： 10.1016/j.canlet.2008.06.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  22 in total

1.  Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.

Authors:  Hyung Gyun Kim; Tran Thi Hien; Eun Hee Han; Yong Pil Hwang; Jae Ho Choi; Keon Wook Kang; Kwang-il Kwon; Bong-Hee Kim; Sang Kyum Kim; Gye Yong Song; Tae Cheon Jeong; Hye Gwang Jeong
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.

Authors:  Pushpendra Kumar Sahu; Raghuvir Singh Tomar
Journal:  J Biol Chem       Date:  2019-01-18       Impact factor: 5.157

Review 3.  Helminthes and insects: maladies or therapies.

Authors:  Nora L El-Tantawy
Journal:  Parasitol Res       Date:  2014-12-30       Impact factor: 2.289

4.  Towards novel anti-tumor strategies for hepatic cancer: ɛ-viniferin in combination with vincristine displays pharmacodynamic synergy at lower doses in HepG2 cells.

Authors:  Filiz Özdemir; Gülşen Akalın; Mesut Şen; Nur Ipek Önder; Arzu Işcan; H Mehtap Kutlu; Zerrin Incesu
Journal:  OMICS       Date:  2013-12-17

Review 5.  Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.

Authors:  Chung-Pu Wu; Shinobu Ohnuma; Suresh V Ambudkar
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

Review 6.  Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  Bioorg Med Chem       Date:  2021-01-09       Impact factor: 3.641

7.  CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation.

Authors:  Gen Zhang; Lixin Shi; Matthias Selke; Xuemei Wang
Journal:  Nanoscale Res Lett       Date:  2011-06-13       Impact factor: 4.703

8.  Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.

Authors:  Yu-Jen Chen; Cheng-Deng Kuo; Szu-Han Chen; Wei-Jen Chen; Wen-Chien Huang; K S Clifford Chao; Hui-Fen Liao
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2).

Authors:  Gustavo Jabor Gozzi; Amanda do Rocio Andrade Pires; Glaucio Valdameri; Maria Eliane Merlin Rocha; Glaucia Regina Martinez; Guilhermina Rodrigues Noleto; Alexandra Acco; Carlos Eduardo Alves de Souza; Aurea Echevarria; Camilla Moretto Dos Reis; Attilio Di Pietro; Sílvia Maria Suter Correia Cadena
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

10.  Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.

Authors:  Wei Li; Dao-Ming Li; Kai Chen; Zheng Chen; Yang Zong; Hong Yin; Ze-Kuan Xu; Yi Zhu; Fei-Ran Gong; Min Tao
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.